# US 2013/0280324 A1 · Sustained release pharmaceutical compositions comprising pregabalin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280324 A1
- Document ID: US20130280324A1
- Status: Published application
- Kind: A1
- Application number: 13/824,188
- Filed: 2011-09-15
- Published: 2013-10-24
- Earliest claimed: 2010-09-17
- Assignees: Panacea Biotec Limited
- Inventors: Rajesh Jain; Sarabjit Singh; Shivanand Puthli
- Web page: https://patentgrep.com/patent/US20130280324A1

## CPC

- A61K 9/0002: {Galenical forms characterised by the drug release technique; Application systems commanded by energy}
- A61K 9/1623: {Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 31/197: the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid (carnitine A61K31/205)
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.

## Claims

### Claim 1

A sustained release pharmaceutical composition adapted for once daily dosing, comprising pregabalin or a pharmaceutically acceptable salt, complex, solvate or hydrate thereof, release retarding agent(s) and optionally other pharmaceutically acceptable excipients thereof, wherein said pharmaceutical composition is bioequivalent to immediate release formulations of pregabalin administered twice daily.

### Claim 2 (depends on 1)

A sustained release pharmaceutical composition according to claim 1, wherein the release retarding agent is selected from the group consisting of cellulose ethers, cellulose esters, acrylic acid copolymers, waxes, gums, glyceryl fatty acid esters and sucrose fatty acid esters.

### Claim 3 (depends on 2)

A sustained release pharmaceutical composition according to claim 2, wherein the sucrose fatty acid ester is selected from the group comprising, sucrose stearate, sucrose distearate, sucrose palmitate, sucrose oleate, sucrose laurate, sucrose behenate, sucrose erucate and combinations thereof.

### Claim 4 (depends on 1)

A sustained release pharmaceutical composition according to claim 1, wherein the composition comprises pregabalin in an amount from about 25% to about 75% by weight of the dosage form and release retarding agent in an amount from about 20% to about 80% by weight of the dosage form.

### Claim 5 (depends on 1)

A sustained release pharmaceutical composition according to claim 1, comprising
a) 30% to 50% w/w of pregabalin or a pharmaceutically acceptable salt, complex, solvate or hydrate thereof
b) 30% to 60% w/w of sucrose fatty acid ester
c) Optionally 1%-50% w/w of pharmaceutically acceptable excipients

### Claim 6 (depends on 1)

A sustained release pharmaceutical composition according to claim 1, wherein the composition exhibits an in vitro release of atleast about 25% of pregabalin after 6 hours and atleast about 50% of pregabalin after 12 hours and in an aqueous medium.

### Claim 7 (depends on 1)

A sustained release pharmaceutical compositions according to claim 1, in which the compositions exhibits an in vitro release of at least about 75% of pregabalin after 24 hours in an aqueous medium.

### Claim 8 (depends on 2)

A process for the preparation of a pharmaceutical composition according to claim 2, wherein the process comprises mixing pregabalin; sucrose fatty acid ester and optionally other pharmaceutical excipients, granulating the resultant blend compressing the granules into a tablet or filling into a hard gelatin capsule.

### Claim 9 (depends on 8)

A process for the preparation of a pharmaceutical composition according to claim 8 comprising the following steps:
Step 1. Mixing pregabalin; sucrose fatty acid ester and optionally other pharmaceutical excipients,
Step 2. Making slugs of resultant mixture as obtained in step 1
Step 3. Breaking down the slugs obtained in step 3 to obtain the granules of desired size
Step 4. Optionally mixing the granules of step 3 with other excipients to obtain final blend.
Step 5. Compressing the resultant blend of step 4 to obtain tablets or filling such final blend into hard gelatin capsules.

### Claim 10 (depends on 1)

A sustained release composition according to claim 1, wherein pharmaceutical composition administered once daily exhibits an AUC of pregabalin ranging from 10 μg/ml to 100 μg/ml.

### Claim 11 (depends on 10)

A sustained release composition according to claim 10, wherein pharmaceutical composition administered once daily exhibits an AUC of pregabalin ranging from 30 μg/ml to 80 μg/ml.

### Claim 12 (depends on 10)

A sustained release composition according to claim 10, wherein pharmaceutical composition administered once daily exhibits an AUC of pregabalin ranging from 40 μg/ml to 60 μg/ml.

### Claim 13 (depends on 1)

A sustained release composition according to claim 1, wherein pharmaceutical composition administered once daily provides peak plasma concentrations of pregabalin ranging from 1 μg/ml to 10 μg/ml.

### Claim 14 (depends on 13)

A sustained release composition according to claim 13, wherein pharmaceutical composition administered once daily provides peak plasma concentrations of pregabalin ranging from 2.5 μg/ml to 8 μg/ml.

### Claim 15 (depends on 13)

A sustained release composition according to claim 13, wherein pharmaceutical composition administered once daily provides peak plasma concentrations of pregabalin ranging from 3.5 μg/ml to 6 μg/ml.

### Claim 16

A sustained release pharmaceutical composition adapted for once daily dosing, comprising pregabalin or a pharmaceutically acceptable salt, complex, solvate or hydrate thereof, release retarding agent(s) and optionally other pharmaceutically acceptable excipients thereof, wherein said pharmaceutical composition is bioequivalent when compared in terms of total exposure (AUC) to conventional immediate release composition of pregabalin administered thrice daily.

### Claim 17

A sustained release composition as herein above described in the specification with reference to the accompanying drawing.
